You just read:

Isotope Technologies Garching GmbH Announces In-licensing of DOTA-Zoledronate for Bone Targeted Radionuclide Theranostics of Osseous Metastases

News provided by

ITM Isotopen Technologien München AG

Aug 20, 2015, 08:35 ET